Internatl. Pharmaceutical Products
Executive Summary
Company announced an exclusive U.S./Canada licensing agreement with the Italian firm Laboratorios Cusi, covering manufacture and distribution of timolol maleate for treatment of glaucoma. Merck currently sells the beta blocker in the U.S. under the brand name Timoptic. U.S. sales are estimated at $130 mil. per year.
You may also be interested in...
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.